Fount of Information

AcroBiosystems社 Johnson & Johnson and Xencor establish a new milestone cooperation

この製品に関するご意見・ご照会・お問合せはこちら

Comprehensive_ADC_target_1.png

 Products

Support

Scientific Talk

COVID-19 R&D

About Us

  

 Johnson & Johnson and Xencor establish a new milestone cooperation

   


 

Xencor_news.pnghttps://xencor.com/  

News Express

 

On October 4, 2021, Johnson & Johnson and Xencor reached a cooperation agreement that Johnson & Johnson paid $100 million in advance and made a $25 million equity investment in Xencor. In addition, it needed to pay a milestone amount of $1.188 billion to jointly develop and commercialize plamotamab (CD20 x CD3 bispecific antibody) and novel XmAb® B-cell targeting bispecific antibodies.

 

In September 2021, the Center for Drug Evaluation (CDE) of China announced that Roche's CD3/CD20 bispecific antibody RO7030816 (Mosunetuzumab) has obtained clinical trial implied permission for the treatment of relapsed/ refractory follicular lymphoma.

 

Targeting CD20 and CD3, the witness and creator in the process of antibody-drug development

 

Targeting CD20 and CD3 can offer a great prospect with regard to antibody drug development. In addition to monoclonal antibodies, pharmaceutical companies have turned the research and development of bispecific antibodies. It has set off a new upsurge in CD20/CD3 bispecific antibody drug development.

 

read_more.PNG

  


 

To facilitate the development of drugs targeting CD20 and bispecific T-cell engager antibodies, ACROBiosystems is providing full-length CD20 expressed by HEK293 and a series of high-quality CD3 proteins.

 

>> Click here to learn more about full-length CD20 proteins and verification data with free protocols

 


  


 

HEK293.jpg

 

CD3.jpg

 

click_here.PNG 


 


 

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。